April 4, 2019 6:54pm

It’s not hard to be right so often, it’s about refining expectation, defining insight and NOT being indentured to ANY financial institution! That’s why my “quantamental” blend of the two styles has become common parlance among investors and traders.

Financings: Pluristem Therapeutics (PSTI -$0.282 to $0.57) priced its offering of 27,142,858 shares and warrants at $0.70 per share expecting $20 M.

Pre-open indications: 10 HITs and 0 MISS

 

Duty, honor and shareholders should be a mantra – it’s mine!

I remind those of the latest vehicles of fielding visibility and volatility of two magic words – news and transparency!

 

Markets and indexes:

  • The Dow closed up +147.96 points or +0.56% to 26,366.09
  • The S&P closed up +5.99points or +0.21% at 2,879.39
  • The NASDAQ was down -3.77 points or -0.05% to 7,891.78

 

Henry’omics:

As I had expected, the sector “slid down the slide” of the overbought while the NASDAQ also fell along with the IBB.

After so many up sessions, it was time for a decline if … traders didn’t do it the algorithms would have done it for them – as if they didn’t.

It’s an honor to be considered the “canary in the (sectors) coal mine”!  I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors in the perception of sector vulnerabilities and strengths – it’s more than opinion, the facts and truth need to be recognized!

RMi outlines preludes and aftermaths of sector as related to market activities.

 

The advance/decline line scenario of 45 covered companies:  

  • The open was negative with the A/DL to 11/33, 0 flats and 1 acquired (AST);
  • The mid-day negative with an A/DL of 9/35 and 1 flat and 1 acquired;
  • The close was negative with an A/DL of 14/30 and 0 flat and 1 acquired;

 

Pre-open post, “I am still transmuting share pricing’s value.”

 

My pre-open indications: 10 HITs and 0 MISS

  • Pluristem Therapeutics (PSTI) closed down -$0.29 – hit;
  • Sangamo Therapeutics (SGMO) closed down -$0.39 – hit;
  • bluebird bio (BLUE) closed down -$5.12 – hit;
  • Biostage (BSTG) closed down -$0.10 – hit;           
  • CRISPR Therapeutics (CRSP) closed down -$0.09 – hit;
  • Editas Medicine (EDIT) closed down -$0.08 – hit;
  • Intellia Therapeutics (NTLA) closed down -$0.14 – hit;
  • ReNeuron Group (RENE.L) closed up +$33.00 – hit;
  • Sangamo Therapeutics (SGMO) closed down -$0.89 – hit;
  • Verastem Oncology (VSTM) closed up +$0.06 – hit;

 

Cell and gene therapy company’s worst-performers were: 

  • BLUE (-$5.14), IONS (-$2.74), RARE (-$1.98), SGMO (-$0.89) and VYGR (-$0.86)
  • RENE.L (-$2.00), ONCE (-$1.11), RGNX (-$0.54), ALNY (-$0.51) and FIXX (-$0.36)
  • RENE.L (-$1.50), QURE (-$0.40), STML (-0.12), VCEL (-$0.12) and MDXG (-$0.10)
  • ALNY (-$1.62), SAGE (-$1.20), BOLD (-$1.19), BLFS (-$0.28) and CRSP (-$0.27)

Sector equities posting gains were:

  • RENE.L (+$33.00), QURE (-$3.52), BMRN (-$0.49), BOLD (+$0.37) and FIXX (+$0.19)
  • GBT (+$3.71), SGMO (+$0.74), CLLS (+$0.87), ADVM (+$0.25) and MDXG (+$0.16)
  • SGMO (+$2.76), RARE (+$2.63), SAGE (+$2.48), CRSP (+$2.45) and BLUE (+$1.82)
  • RENE.L (+$22.00), MDXG (+$0.20), MESO (+$0.28), FIXX (+$1.41) and STML (+$0.55)

 

Tonight’s percentage (%) indicators: 

  • Range of the 14 upside was +0.05% (OSIR) to +27.27% (RENE.L) while the 33 downside ranged from -0.16% (ONCE) to -32.75% (PSTI).

Volume stats: 

  • 4 out of the 14 upside had higher (than the 3 month average) volume
  • 14 out of the 33 downside experienced greater volume (than the 3 month average)

0 flat – with 1 acquired: 1 (AST)

 

The iShares NASDAQ Biotechnology (IBB) indicator:

  • Thursday was down -0.41%;
  • Wednesday was up +0.59%;
  • Tuesday was up +0.81 %;
  • Monday was up +0.10 %;
  • Friday was up +2.14 %;
  • Last Thursday was up +0.61%;

 

April sessions:

Thursday closed NEGATIVE with 30 decliners, 14 advancers, 0 flat and 1 acquired (AST);

Wednesday closed POSITIVE with 16 decliners, 27 advancers, 1 flat and 1 acquired (AST);

Tuesday closed POSITIVE with 11 decliners, 32 advancers, 1 flat and 1 acquired (AST);

Monday (4/1) closed POSITIVE with 19 decliners, 23 advancers, 2 flats and 1 acquired (AST);

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.